Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 226,613,919 papers from all fields of science
Search
Sign In
Create Free Account
Antigens, CD25
Known as:
CD25 antigen
, CD25 Ag
, tac antigen (IL2 receptor)
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
CD25 Ag:PrThr:Pt:Tiss:Ord:Immune stain
IL2RA gene
IL2RA wt Allele
Broader (2)
Differentiation Antigens
Receptors, Cytokine
Narrower (2)
IL2RA protein, human
Interleukin 2 Receptor, Alpha
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies
Jaewoong Lee
,
K. Kume
,
+22 authors
M. Müschen
Blood
2018
Corpus ID: 198297248
Studying gene expression and clinical outcome data from 136 clinical trials for patients with cancer (~21,000 patients with 26…
Expand
2016
2016
A2.01 The expansion of CD25highIL-10highFOXP3high B regulatory cells is in association with sle disease activity
E. Toubi
,
Z. Vadasz
2016
Corpus ID: 87234014
B regulatory cells (Bregs) belong to a subgroup of activated B cells tasked with maintaining self-tolerance and preventing…
Expand
2016
2016
Correlation of Expression of CD25 in Hematopoietic Stem/Progenitor Cell Fraction of Bone Marrow Cells with Response to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Patients
Daiki Karigane
,
H. Kasahara
,
+15 authors
S. Okamoto
2016
Corpus ID: 208404351
Introduction: Tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis of chronic myelogenous leukemia (CML…
Expand
2016
2016
Combined Cancer Immunotherapy Against Aurora Kinase A
I. Kaštánková
,
I. Poláková
,
M. Dušková
,
M. Šmahel
Journal of immunotherapy
2016
Corpus ID: 25038960
Aurora kinase A (AURKA) is a centrosomal protein that is overexpressed in a number of human malignancies and can contribute to…
Expand
2014
2014
suppression of STAT 5 activation and degradation of MYC oncogene PIM inhibitors target CD 25-positive AML cells through concomitant
Zhuyan Guo
,
Anlai Wang
,
+20 authors
Shih-Min A. Huang
2014
Corpus ID: 207790428
Adrian, Marion Dorsch, Carlos Garcia-Echeverria and Shih-Min A. Huang Christoph Lengauer, Stefan Gross, Bailin Zhang, Hong Cheng…
Expand
2009
2009
Negative effect of IFN-α2b against HBV-DNA in PBMC, serum and inducement to CD25 in the patients with chronic hepatitis B
Jian Wang
,
Lin Sun
,
Gui-ju Xiang
,
Xiao-bin Hu
IEEE International Symposium on IT in Medicine…
2009
Corpus ID: 40309437
Objective: To study the effect of IFN-α2b on HBVDNA and inducement to CD25 of the patients with chronic hepatitis B. Methods: All…
Expand
2008
2008
Anti CD25 treatment of human dendritic cells modulates both their cytokine synthesis profiles and their capacity to activate allogeneic CD4 T cells: a potential tolerogenic effect.
K. Mnasria
,
C. Lagaraine
,
J. Manaa
,
Y. Lebranchu
,
R. Oueslati
International Immunopharmacology
2008
Corpus ID: 7724293
2008
2008
353: Generation of Treg-like Cells from CD4+CD25- T cells via Epigenetic Modification using a Demethylating Agent Decitabine
Jaebok Choi
,
Julie Ritchey
,
J. Dipersio
2008
Corpus ID: 57700085
2006
2006
SI12 Lymphocyte Subsets Following Autologous Transfer of CD25 Depleted Leukapheresis Products
E. Austin
,
F. Thistlethwaite
,
+9 authors
R. Hawkins
2006
Corpus ID: 72085647
A subset of T lymphocytes known as regulatory T‐cells (Tregs) plays a pivotal role in suppressing the immune system in particular…
Expand
1998
1998
Targeting of saporin to Hodgkin's lymphoma cells by anti‐CD30 and anti‐CD25 bispecific antibodies
S. Sforzini
,
D. de Totero
,
+5 authors
S. Ferrini
British Journal of Haematology
1998
Corpus ID: 24342788
CD25 and CD30 represent suitable target molecules for bispecific antibody (bimAb)‐driven toxin delivery to lymphoid tumour cells…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE